McPhail Mark J W, Kriese Stephen, Heneghan Michael A
Institute of Liver Studies, King's College Hospital, London, UK.
Curr Opin Gastroenterol. 2015 May;31(3):209-14. doi: 10.1097/MOG.0000000000000174.
Acute liver failure (ALF) is a rare but life-threatening systemic disorder. Survival rates with or without emergency liver transplantation (ELT) are increasing. The benefit of ELT in some cases has been questioned and the potential for survival with medical management alone is changing our approach to the management of this disease.
Survival rates for all causes of ALF are increasing because of improvements in the care of the critically ill patient. A multifactorial approach involving support of respiratory, circulatory and renal function together with measures to avoid intracranial hypertension, metabolic disequilibrium and sepsis are required. For those who do not respond to these measures or specific antidotes, the selection methods for those likely to benefit from transplantation remain imperfect and novel methods based on the prediction of hepatic regeneration are required. For patients with ALF secondary to acetaminophen overdose, some experts believe a randomized controlled trial is required to find those most likely to benefit from ELT.
ALF remains a life-threatening condition with a high mortality rate requiring prompt support of multiorgan failure. Historical listing criteria for ELT are being questioned and improvement in medical management offers the option of continued improvements in transplant-free survival.
急性肝衰竭(ALF)是一种罕见但危及生命的全身性疾病。无论是否进行紧急肝移植(ELT),生存率都在提高。ELT在某些情况下的益处受到质疑,仅通过药物治疗实现生存的可能性正在改变我们对这种疾病的管理方法。
由于危重症患者护理水平的提高,各种原因导致的ALF生存率都在上升。需要采取多因素方法,包括支持呼吸、循环和肾功能,以及采取措施避免颅内高压、代谢失衡和败血症。对于那些对这些措施或特定解毒剂无反应的患者,选择可能从移植中获益的患者的方法仍然不完善,需要基于肝再生预测的新方法。对于对乙酰氨基酚过量导致的ALF患者,一些专家认为需要进行一项随机对照试验,以找出最有可能从ELT中获益的患者。
ALF仍然是一种危及生命的疾病,死亡率很高,需要迅速支持多器官功能衰竭。ELT的历史列入标准受到质疑,药物治疗的改善为无移植生存的持续改善提供了选择。